Main Uses of Aluvia

Aluvia is an antiretroviral medication used in the management of human immunodeficiency virus (HIV-1) infection. It is a fixed-dose combination therapy containing two active substances: lopinavir and ritonavir. This medication is indicated for use in both adults and children, typically as part of a combination regimen with other antiretroviral agents.

Mechanism of Action

The two components of Aluvia work together to control the virus:

• Lopinavir: This is a protease inhibitor. It works by blocking the activity of HIV protease, an enzyme the virus requires to replicate and create new infectious viral particles.
• Ritonavir: While also a protease inhibitor, its primary role in this combination is as a pharmacokinetic enhancer or "booster." It slows down the breakdown of lopinavir in the liver, ensuring that levels of lopinavir remain high enough in the bloodstream to be effective against the virus.

Therapeutic Benefits

The primary goal of Aluvia therapy is to manage the progression of HIV infection and support the immune system.

Viral Suppression

By inhibiting the replication of the virus, Aluvia helps reduce the viral load—the amount of HIV present in the blood—to very low or undetectable levels. Maintaining a low viral load is essential for preventing damage to the immune system and reducing the risk of illness.

Immune System Support

When viral replication is controlled, the immune system has a better opportunity to recover or maintain its function. This is often measured by an increase in CD4+ T-cell counts, which are white blood cells that play a vital role in protecting the body against infections.

Long-term Management

As a component of antiretroviral therapy (ART), Aluvia contributes to the long-term management of HIV as a chronic condition. Effective treatment helps prevent the progression of the infection to more advanced stages and reduces the frequency and severity of opportunistic infections.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility to Use Aluvia (Lopinavir/Ritonavir)

The use of Aluvia is strictly defined by regulatory eligibility criteria across various patient populations. It is indicated for use in adults, adolescents, and pediatric patients starting from 14 days of age.

---

Absolute Contraindications

Aluvia must not be used in specific patient populations, as mandated by regulatory authorities:

• Severe Hepatic Impairment: Patients with severe liver insufficiency are strictly prohibited from using the medicine.
• Hypersensitivity: Individuals with a known, clinically significant allergy to lopinavir, ritonavir, or any of the product's components.
• Neonates: The oral solution formulation is contraindicated in neonates below specific postmenstrual and postnatal age thresholds.

---

Conditional Use and Restrictions

Use is subject to specific regulatory limitations in other groups:

• Cardiac Conditions: Use must be avoided in patients with Congenital Long QT Syndrome or uncorrected hypokalemia. Caution is also warranted for those with pre-existing conduction system disease.
• Hepatic Status: While severe impairment is prohibited, use in mild to moderate hepatic impairment is permitted, though careful monitoring is often advised.
• Dosing Regimen: The once-daily dosing regimen is not recommended for pregnant women or pediatric patients younger than 18 years.
• Lactation: Breastfeeding is not recommended for mothers with HIV infection.

The official interaction profile for Aluvia is defined by its substantial influence on the body's drug-metabolizing systems, primarily as a potent inhibitor of the CYP3A enzyme. This pharmacokinetic interaction can lead to significantly increased plasma concentrations of co-administered medicines that are metabolized by CYP3A, resulting in formal constraints. Regulatory documents therefore list numerous agents, including certain antiarrhythmics (e.g., Amiodarone), antihistamines, and statins (e.g., Lovastatin, Simvastatin), as contraindicated combinations due to the high risk of serious and life-threatening adverse reactions.

The medicine's effectiveness is also sensitive to enzyme-inducing agents. Strong CYP inducers like Rifampicin and the herbal supplement St. John's Wort are prohibited because they can significantly reduce Lopinavir plasma concentrations, potentially causing loss of therapeutic response. Conversely, co-administration with other inducers, such as Efavirenz, requires an increase in the Lopinavir/Ritonavir dose to maintain adequate exposure.

The regulatory profile notes population-specific cautions, including the formal restriction that Aluvia is contraindicated in patients with severe hepatic impairment. The oral solution formulation contains alcohol, which mandates a restriction with medicines like Disulfiram or Metronidazole. Additionally, co-administration with the liquid form of Didanosine requires a mandatory separation of dose administration by at least one hour.

Aluvia is a fixed-dose combination of the antiretroviral agents Lopinavir (LPV) and Ritonavir (RTV).

Lopinavir is an aspartate protease inhibitor that acts at the active site of the HIV-1 protease enzyme. LPV competitively binds to this site, thereby preventing the enzyme from performing the necessary cleavage of the Gag and Gag-Pol polyproteins. The resulting uncleaved polyproteins yield non-functional structural components and enzymatic proteins (such as reverse transcriptase and integrase), which subsequently inhibit the maturation and final assembly of new viral particles. This process reduces the intracellular synthesis of functional viral proteins.

Ritonavir functions as a pharmacokinetic enhancer by acting as a selective inhibitor of the Cytochrome P450 3A (CYP3A) isoenzyme, the enzyme primarily responsible for LPV's metabolism. This inhibition reduces the oxidative breakdown of Lopinavir, increasing its plasma concentration and prolonging its half-life. This ensures sustained systemic exposure to Lopinavir.

The medicine known as Lopinavir/Ritonavir is administered exclusively via the oral route in the form of film-coated tablets, oral solution, or oral granules. The standard dose for adults is 400 mg Lopinavir / 100 mg Ritonavir taken twice daily. An alternative, higher dose of 800 mg Lopinavir / 200 mg Ritonavir taken once daily is reserved only for specific adult patients who have a low level of lopinavir resistance-associated mutations and are not taking certain co-medications.

Regarding administration conditions, the film-coated tablets may be taken with or without food, providing flexibility in the dosing schedule. However, the oral solution and oral granules must be taken with food to ensure correct drug absorption. All tablets must be swallowed whole and must not be crushed, broken, or chewed.

Dosing for pediatric patients (14 days and older) is determined by calculated Body Weight or Body Surface Area. The once-daily regimen is not recommended for any patient under the age of 18. Furthermore, the oral solution must not be initiated in neonates who have not yet reached 42 weeks postmenstrual age AND 14 days postnatal age. If a dose is missed, the patient should take the dose as soon as possible, unless it is almost time for the next dose, in which case the missed dose should be skipped.

Research evidence / Overview of Studies for Aluvia

Evidence for Chronic Management of HIV-1 Infection

The core evidence base for the lopinavir/ritonavir combination is derived primarily from Randomized Controlled Trials (RCTs) and systematic reviews that have explored the combination's application in the long-term context of the viral condition. These studies, which included both adults and pediatric patients, were designed to observe changes related to the viral infection over time. Researchers examined two critical outcomes: the reduction of the Viral Load and the trajectory of CD4+ T-cell counts, a key marker of immune status.

Studies reported measurements related to viral suppression in patient groups, describing a change in the quantity of the virus in the blood. Research describes patterns of change measured related to CD4+ T-cell counts. Since this medicine is nearly always used alongside other antiretroviral drugs in combination therapy, definitively separating its effects from the other components is complex. Research continues to address the full profile of the medicine’s long-term use, especially in the context of viral mutations and resistance that can occur.

---

Evidence for Advanced HIV Disease and Immune System Decline

The medicine was studied for use in patient groups with Advanced HIV Disease (AIDS) and significant Immune System Decline (low CD4+ T-cell counts). The research included prospective trials and extensive observational cohorts. These studies monitored key clinical outcomes such as progression to AIDS-defining illnesses and overall patient health metrics.

Findings describe patterns observed in the studies, including measurements related to decreases in the Viral Load and subsequent increases in CD4+ T-cell counts. Clinical observations described patterns related to the occurrence of AIDS-defining illnesses over the follow-up periods in some trial settings. Evidence related to the observed changes in CD4+ counts suggests that research has explored its role in supporting Immune Reconstitution.

---

Areas of Research Uncertainty and Study Limitations

While the evidence base is substantial, research highlights what is known and what is still uncertain. Evidence quality varies across studies, especially for outcomes related to general patient well-being, where symptom reporting can be subjective.

A key limitation is that the medicine functions as a fixed-dose combination and is a component of a multi-drug regimen; this means that comparative evidence is limited when attempting to attribute all observed effects solely to this combination. Also, the findings were mixed or data are still emerging regarding the full profile of long-term effects. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
2. Lopinavir + ritonavir - WHO Electronic Essential Medicines List (eEML)
3. WHO Public Assessment Report (WHOPAR) Kaletra (Lopinavir/Ritonavir 200mg/50mg film-coated tablets)

Common questions about Aluvia (FAQ)

Q: Why do people sometimes call Aluvia by the name Kaletra?

A: Aluvia is the trade name for the fixed-dose combination of lopinavir and ritonavir used in some regions. However, in many other parts of the world, including the United States, this medicine is known by the brand name Kaletra. Regulatory and informational documents often use both names when referring to the same drug composition.

Q: Is it normal to feel tired after starting to take Aluvia?

A: Official safety data indicates that experiencing tiredness or asthenia, which is a feeling of unusual weakness or lack of energy, is described as a commonly reported event observed in patients during clinical trials. This is a recognized adverse reaction described in the official product information.

Q: Does Aluvia need to be stored in the refrigerator or is room temperature okay?

A: The required storage condition depends on the exact form of the medicine. The film-coated tablets are required to be stored at a controlled room temperature, typically 20°C to 25°C. In contrast, the oral solution has a requirement for refrigeration but may be stored at room temperature for a limited duration (up to 2 months).

Q: Are there any common foods or drinks I should avoid while on Aluvia?

A: Official information notes that the oral solution form of this medicine contains a small amount of alcohol (ethanol). This alcohol content is a consideration noted in official prescribing information, especially concerning use in children or with certain co-administered medicines.

Q: Can Aluvia affect the results of other blood tests?

A: Yes, official safety data reports that changes in blood tests are commonly observed adverse reactions. Specifically, increases in blood fat levels, such as triglyceride and cholesterol levels, are noted in the official product information.

Q: What does 'resistance' mean when talking about taking Aluvia?

A: In the context of this medicine and HIV treatment, resistance refers to the ability of the Human Immunodeficiency Virus to mutate and change its structure. If the virus develops resistance, it can cause the medicine to become less effective at controlling the infection over time.

Q: Can older adults (seniors) safely use Aluvia?

A: Regulatory documents contain a specific section addressing the use of this medicine in the geriatric population (older adults). Official product information notes that use requires careful consideration due to the potential for age-related factors, such as decreased liver function, that may influence the drug's exposure.

Q: Does Aluvia cause any noticeable changes to a person's mood or sleep patterns?

A: Official safety data indicates that disturbances to sleep patterns have been reported. Specifically, trouble with sleeping (insomnia) has been listed as a less common adverse reaction observed in patients.

Q: How is the dose of Aluvia typically adjusted for a child?

A: Dosing for pediatric patients is determined by a specific calculation. The amount of medicine is calculated based on the child’s Body Weight (in milligrams per kilogram) or their Body Surface Area (in mg/ m^2), as required for therapeutic guidance.

Q: Does Aluvia cause liver issues or affect kidney function?

A: Official safety information lists potential effects on the liver (Hepatobiliary Disorders), including warnings about severe Hepatotoxicity (liver damage) and contraindications for patients with severe hepatic impairment. Official documentation emphasizes concerns related to liver function, while effects on kidney function are not cited as a primary safety concern in the same context.

Q: Are there any specific concerns about taking Aluvia if I have diabetes?

A: Official safety documents contain a specific section detailing warnings and precautions related to Diabetes Mellitus and Hyperglycemia (high blood sugar), which may necessitate medical management. These effects are noted as potential adverse reactions.

Q: How long does the drug stay in my system after I stop taking it?

A: Based on published pharmacokinetic data, the amount of lopinavir in the body decreases relatively quickly. The effective half-life of lopinavir over the usual dosing interval is described as approximately 5 to 6 hours.

Q: What are official documents saying about Aluvia and cholesterol levels?

A: Official documents classify hypercholesterolemia (high cholesterol levels) and hypertriglyceridemia as commonly reported adverse reactions. This finding is reflected in the official side effects section, which classifies high cholesterol as a commonly reported adverse reaction observed in clinical trials.

Q: Is there published evidence about Aluvia's use in younger children?

A: Yes, the medicine is formally indicated for use in pediatric patients starting from 14 days of age. Regulatory documents include dosing and safety information based on studies specific to infants and younger children.

Q: What happens if Aluvia is taken with an herbal supplement like St. John's Wort?

A: Official documents state that St. John’s Wort is contraindicated (prohibited) because its enzyme-inducing effects can significantly reduce the concentration of the medicine in the blood, potentially leading to loss of viral control. This combination is formally restricted in the product information.

Q: Can Aluvia impact the effectiveness of birth control pills?

A: Regulatory information notes that this medicine may reduce the efficacy (effectiveness) of combined hormonal contraceptives. Because of this potential interaction, the need for an effective alternative or an additional barrier method of contraception is often highlighted in the prescribing information.

Q: Is Aluvia approved for use during pregnancy?

A: Official guidance states that the medicine is only authorized for use during pregnancy when the potential benefit is determined to clearly outweigh the potential risk to the fetus. The once-daily regimen is specifically not recommended for use in pregnant women.

Q: Can I use Aluvia by people who have hepatitis B or C?

A: Official documents note that use requires careful consideration for patients with liver disease, including chronic Hepatitis B or C infection, due to the potential for liver-related adverse effects.

Q: Is it true that Aluvia can cause changes in the body's fat distribution?

A: Official safety documentation recognizes fat redistribution (lipodystrophy) as a potential effect associated with the long-term use of combination antiretroviral therapies, including this medicine.

How to Store and Dispose of Lopinavir/Ritonavir (Aluvia)

The storage requirements for Lopinavir/Ritonavir are specific to the dosage form to maintain stability and potency.

---

Official Storage Conditions

Dosage Form	Required Storage Condition
Film-Coated Tablets	Store at controlled room temperature (20 C to 25 C). Keep in the original container, tightly closed, and protect from excess moisture and light.
Oral Solution	Store under refrigeration (2 C to 8 C). Do not freeze. If stored at room temperature (below 25 C), it must be used within 2 months.

All forms of this medication must be kept out of the sight and reach of children, and all safety caps must be locked. Unused or expired medication must be managed according to regulated procedures, typically through an approved drug take-back program. Medicines should not be flushed down the toilet or poured into a drain unless specific instructions are provided by health authorities.